Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis
Journal of Periodontology · 2023-02 · 94 (2) · 244-255
DOI: 10.1002/jper.22-0211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Periodontology, online erschienen am 08.11.2022. Verfasst von Yuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Sto…. Hauptthemen laut MEDLINE: Alveolar Bone Loss, Periodontitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
The aim of this study was to compare the effects of two osteoanabolic drugs, abaloparatide (ABL) and teriparatide (TPTD), on protecting alveolar bone in experimental periodontitis.
Methods
Twenty‐four 9‐week‐old, male, Sprague‐Dawley rats were placed with silk suture around the right maxillary second molar, and then were randomly divided into three groups, that is, the ABL, TPTD, and saline group, receiving intermittent subcutaneous injections of ABL (80 μg/kg), TPTD (80 μg/kg) or saline respectively every other day for 4 weeks. Samples on both sides were assessed through micro‐computerized tomography, histological, and immunohistochemical analysis. Mouse pre‐osteoblast MC3T3 cell was cultured with lipopolysaccharide (LPS) and treated with ABL or TPTD, before assays of cell proliferation, alkaline phosphatase (ALP) activity and real‐time polymerase chain reaction.
Results
On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss, and ABL had significantly better effects with higher expression of runt‐related transcription factor 2 (RUNX2) and Bglap (formerly called osteocalcin); meanwhile, the ligature induced osteoclastogenesis and down‐regulation of osteoprotegerin (OPG) was affected by neither drug. On the non‐ligature side, ABL also showed better osteoanabolic effects. In vitro studies revealed that, in the presence of LPS, ABL, and TPTD similarly promoted MC3T3 proliferation, whereas ABL induced higher ALP activity and osteoblastic gene expression compared to TPTD.
Conclusion
Both ABL and TPTD protect and regenerate alveolar bone in experimental periodontitis, and ABL behaves even better than TPTD at the same dose, attributed to its stronger osteoanabolic effects in this context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Zitieren
APA
Li, Y., Qian, Y., Qiao, H., Pan, W., Xie, L., & Li, Y. (2023). Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis. Journal of Periodontology, 94(2), 244-255. https://doi.org/10.1002/jper.22-0211
Vancouver
Li Y, Qian Y, Qiao H, Pan W, Xie L, Li Y. Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis. Journal of Periodontology. 2023;94(2):244-255. doi:10.1002/jper.22-0211
BibTeX
@article{Li2023,
author = {Li, Yuan and Qian, Yuran and Qiao, Hui and Pan, Weiyi and Xie, Liang and Li, Yu},
title = {Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis},
journal = {Journal of Periodontology},
year = {2023},
volume = {94},
number = {2},
pages = {244--255},
doi = {10.1002/jper.22-0211}
}
EUVIMED